Clinics in liver disease · 2018
Current Treatment Options for Primary Biliary Cholangitis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Kimberly A, Bahar Runalia, Liu Chung H, Bowlus Christopher L
Аннотация
Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.
Предметные рубрики MeSH
Alkaline PhosphataseBezafibrateChenodeoxycholic AcidCholagogues and CholereticsComorbidityDrug Therapy, CombinationFenofibrateFibroblast Growth FactorsHumansHypolipidemic AgentsImmunosuppressive AgentsLiver Cirrhosis, BiliaryMalnutritionOsteoporosisPeroxisome Proliferator-Activated ReceptorsReceptors, Cytoplasmic and NuclearUrsodeoxycholic AcidReceptor, Farnesoid X-Activated